Radiopharm Theranostics Limited

NasdaqCM:RADX Stock Report

Market Cap: US$50.8m

Radiopharm Theranostics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of RADX?
Owner TypeNumber of SharesOwnership Percentage
Private Companies59,134,4891.67%
Individual Insiders255,442,8247.21%
Institutions265,166,3557.48%
Hedge Funds320,694,6809.05%
Public Companies537,958,51315.2%
General Public2,105,819,29959.4%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 51.9%.

Top Shareholders

Top 21 shareholders own 40.58% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
15.2%
Lantheus Holdings, Inc.
537,958,513US$7.7m0%no data
9.05%
Regal Partners Limited
320,694,680US$4.6m0%0.22%
4.17%
Paul Hopper
147,721,428US$2.1m0%no data
3.84%
JPMorgan Chase & Co.
136,196,655US$2.0m0%no data
1.59%
Silverarc Capital Management, LLC
56,221,800US$806.2k0%0.1%
1.44%
Stonepine Capital Management LLC
51,000,000US$731.3k0%0.39%
1.22%
NanoMab Technology Limited
43,295,131US$620.8k0%no data
0.92%
Danny Segman
32,500,000US$466.0k0%no data
0.67%
Scarlett Hopper
23,857,142US$342.1k0%no data
0.64%
Riccardo Canevari
22,679,986US$325.2k0%no data
0.52%
HSBC Global Asset Management (UK) Limited
18,411,600US$264.0k-68%no data
0.45%
Phillip Hains
15,956,632US$228.8k0%no data
0.45%
Shared Office Services Pty Ltd
15,839,358US$227.1k0%no data
0.28%
Ian Turner
9,985,292US$143.2k7.89%no data
0.068%
The PNC Financial Services Group, Inc.
2,400,000US$34.4k0%no data
0.03%
Leila Alland
1,071,740US$15.4k0%no data
0.028%
Thomas Tulip
1,000,000US$14.3k0%no data
0.025%
UBS Asset Management AG
900,000US$12.9k-79%no data
0.018%
Hester Larkin
644,247US$9.2k0%no data
0.001%
Rhumbline Advisers Ltd Partnership
36,300US$518.41,920%no data
0.00074%
Aaron Laurita
26,357US$376.10%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/26 08:53
End of Day Share Price 2026/05/26 00:00
Earnings2025/12/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Radiopharm Theranostics Limited is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Yuan ZhiB. Riley Securities, Inc.
Brian Kemp DolliverBrookline Capital Markets